Biomednewsbreaks - CNS Pharmaceuticals Inc.(NASDAQ: CNSP) Enters In Purchase Agreements, Announces Pricing

(MENAFN- Investor Brand Network) CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements are for the purchase and sale of 366,000 shares of common stock, or common stock equivalents in lieu thereof, as part of registered direct offering and warrants to purchase up to 366,000 shares of common stock in a concurrent private placement. The shares will be offered at a combined purchase price of $3.75 per share. According to the announcement, the warrants relating to the concurrent private placement will have an exercise price of $3.62 per share and will be immediately exercisable following the date of issuance; the expiration date for the warrants will be five years from the initial exercise date.

The offering is expected to close today, subject to the satisfaction of customary closing conditions, with gross proceeds totaling an estimated $1.37 million, before standard deductions, fees, and expenses. CNS Pharmaceutical anticipates using the funds for working capital and general corporate purposes.

To view the full press release, visit

About CNS Pharmaceuticals Inc .

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit
.

NOTE TO INVESTORS:
The latest news and updates relating to CNSP are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
...

BioMedWire is powered by
IBN

MENAFN17062024000224011066ID1108342351